Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Angelo who wrote (1843)	3/17/1999 9:01:00 PM
From: Jon Koplik	Read Replies (1) \| Respond to of 2135

Back a month or two ago, when ENMD went up to about $35 a share, my understanding was -- this was in response to news that Thalidomide was now being used to treat various forms of cancer. I am assuming that at least some patients had remission due to the drug. Even though they might die from the cancer eventually flaring up at some point in the future, if the time lag is long, I would characterize it as a case of the drug saving their life. Jon.